M&T Bank Corp Acquires 143 Shares of DaVita Inc. (NYSE:DVA)

M&T Bank Corp lifted its holdings in shares of DaVita Inc. (NYSE:DVA) by 4.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,534 shares of the company’s stock after acquiring an additional 143 shares during the quarter. M&T Bank Corp’s holdings in DaVita were worth $579,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Harvard Management Co. Inc. bought a new position in DaVita in the 2nd quarter worth $55,115,000. KBC Group NV lifted its holdings in DaVita by 27.3% in the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after buying an additional 67,250 shares during the period. BNP Paribas Financial Markets boosted its position in DaVita by 23.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock valued at $47,874,000 after acquiring an additional 56,389 shares in the last quarter. Andra AP fonden grew its holdings in shares of DaVita by 9.0% during the 2nd quarter. Andra AP fonden now owns 192,300 shares of the company’s stock worth $26,647,000 after acquiring an additional 15,800 shares during the period. Finally, abrdn plc raised its position in shares of DaVita by 1.2% in the 3rd quarter. abrdn plc now owns 189,065 shares of the company’s stock worth $30,719,000 after acquiring an additional 2,180 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

DVA opened at $147.53 on Wednesday. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The firm has a market cap of $12.10 billion, a PE ratio of 15.91, a P/E/G ratio of 0.86 and a beta of 0.90. DaVita Inc. has a 1 year low of $103.40 and a 1 year high of $169.51. The stock has a 50-day moving average price of $157.67 and a 200-day moving average price of $150.89.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.76 by ($0.17). The business had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same period last year, the company posted $2.85 earnings per share. Sell-side analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

DVA has been the topic of several recent research reports. Barclays upped their price target on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Truist Financial upped their target price on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, DaVita presently has an average rating of “Hold” and an average target price of $161.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.